This document discusses Inovio Pharmaceuticals' synthetic vaccine technology and development pipeline. It provides an overview of Inovio's synthetic DNA vaccine platform, which uses proprietary SynCon designs and electroporation to generate robust immune responses. The platform aims to treat cancers and infectious diseases by targeting specific antigens without using live or attenuated pathogens. The document summarizes Inovio's clinical trial results demonstrating best-in-class T cell and antibody immune responses. It also outlines Inovio's product development strategy and pipeline, including phase 1 and 2 clinical trials for vaccines against HPV, leukemia, hepatitis C, HIV, and influenza sponsored by Inovio and partnership funding.
Inovio Pharmaceuticals, Inc. Corporate Presentation December 2013Company Spotlight
This document summarizes information presented by Dr. J. Joseph Kim, President and CEO of Inovio Pharmaceuticals, Inc. It discusses Inovio's DNA immunotherapy technology, clinical programs, partnerships, leadership, and upcoming value drivers. Key points include:
- Inovio is developing DNA-based immunotherapies delivered using electroporation for cancers and infectious diseases.
- Their lead program, VGX-3100 for HPV-related cancers, has shown strong T-cell responses and is in Phase II trials with efficacy data expected in mid-2014.
- Inovio has partnerships with Roche for prostate cancer and hepatitis B therapies and external funding to support several clinical programs.
Our technology platform has potential market opportunities in producing therapeutics like vaccines. We are testing the hypothesis that our platform can be scaled up and commercialized cost-effectively. We spoke with experts in vaccine manufacturing, distribution, commercialization of biotech platforms, and more. They validated pain points in current vaccine production and interest in faster, more scalable platforms. Next steps are understanding customer relationships and decision-making to establish a commercialization strategy and business model. We will continue engaging experts and customers.
The document discusses ways to accelerate vaccine development and manufacturing. It proposes adopting a template and platform approach to streamline process development. A template provides a standardized starting point for each vaccine's development process. A platform accumulates expertise across multiple vaccines using common unit operations, parameters, and facilities. This approach can speed development times, lower costs, simplify supply chains, and facilitate technology transfer and manufacturing.
A brief presentation of the market space created by the ongoing ebola epidemic, and projected cost estimates for scale up production vaccine introduction of an ebola vaccine.
Platform Technologies to Accelerate Novel Vaccine Development and ManufacturingMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3jmLYHu
State-of-the-art vaccine technologies are transforming vaccine development, and solutions for fast and reliable production are needed.
The vaccine industry has undergone a revolution in technology resulting in a variety of novel therapeutic platforms that accelerate development and significantly reduce the duration for process optimization and scale-up. However, challenges in maintaining efficacy and improving process robustness remain. In this presentation, we present a comparison of these novel technologies, discuss key considerations for manufacturing and share selected case studies for platforms such as virus-like-particles, viral vectors, plasmid DNA, and mRNA platform.
In this webinar, you will learn:
• Benefits of platform technologies in vaccine development
• Key considerations when deciding between platforms
• Vaccine pipeline analysis and selected case studies
Presented by:
David Loong, Ph.D, Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy
Josephine Cheng, Senior Consultant, Core Modalities Asia Pacific, Bioprocessing Strategy
In this webinar, you will learn:
Trends in vaccine manufacturing
Innovative solutions in facility design
Case studies and proposals for future vaccine factories
Considerations while setting up Quality Management Systems (QMSs)
How validation helps accelerate regulatory approval
Detailed description:
How we see vaccine manufacturing evolving due to the COVID-19 pandemic, how could it further transform, and what are some solutions we can incorporate to prepare ourselves for next-generation facilities?
The unprecedented COVID-19 pandemic has driven significant tech acceleration around the world, including methods of vaccine manufacturing. Together with the concept of Bioprocessing 4.0, digital biomanufacturing enables centralized orchestration of production process and data management, and a "Facility of the Future" characterized by intensified, continuous, predictive, and autonomous operations. In this presentation, we will explore trends in vaccine manufacturing, including fully single-use processes, closed processing, modular facilities, and platform manufacturing. We will also discuss some key considerations when setting up Quality Management Systems for novel facilities, and how to speed up regulatory approval through best practices in facility validation.
Webinar: Re-imagining vaccine manufacturing to address global health challengesMilliporeSigma
Participate in the interactive on demand webinar: http://bit.ly/ReimaginingVaccinesWebinar
In this webinar, you will learn:
- The evolution of vaccine production in response to pandemics and outbreaks
- Key considerations and perspectives on how vaccine processing and facilities could change to address future global health challenges
The document summarizes efforts to develop an HIV vaccine by inducing broadly neutralizing antibodies (bnAbs) through structure-based immunogen design. It describes how bnAbs isolated from infected individuals can inform design of immunogens that expose conserved vulnerabilities on HIV. Challenges include guiding antibody maturation along pathways to bnAbs and understanding how bnAbs develop naturally. Ongoing work includes defining HIV vulnerabilities with additional bnAbs and structures, understanding natural bnAb responses, epitope-directed and trimer-based immunogen design, and evaluating immunogens in collaboration between multiple research institutions. The goal is to develop an HIV vaccine to help curb the global AIDS pandemic.
Inovio Pharmaceuticals, Inc. Corporate Presentation December 2013Company Spotlight
This document summarizes information presented by Dr. J. Joseph Kim, President and CEO of Inovio Pharmaceuticals, Inc. It discusses Inovio's DNA immunotherapy technology, clinical programs, partnerships, leadership, and upcoming value drivers. Key points include:
- Inovio is developing DNA-based immunotherapies delivered using electroporation for cancers and infectious diseases.
- Their lead program, VGX-3100 for HPV-related cancers, has shown strong T-cell responses and is in Phase II trials with efficacy data expected in mid-2014.
- Inovio has partnerships with Roche for prostate cancer and hepatitis B therapies and external funding to support several clinical programs.
Our technology platform has potential market opportunities in producing therapeutics like vaccines. We are testing the hypothesis that our platform can be scaled up and commercialized cost-effectively. We spoke with experts in vaccine manufacturing, distribution, commercialization of biotech platforms, and more. They validated pain points in current vaccine production and interest in faster, more scalable platforms. Next steps are understanding customer relationships and decision-making to establish a commercialization strategy and business model. We will continue engaging experts and customers.
The document discusses ways to accelerate vaccine development and manufacturing. It proposes adopting a template and platform approach to streamline process development. A template provides a standardized starting point for each vaccine's development process. A platform accumulates expertise across multiple vaccines using common unit operations, parameters, and facilities. This approach can speed development times, lower costs, simplify supply chains, and facilitate technology transfer and manufacturing.
A brief presentation of the market space created by the ongoing ebola epidemic, and projected cost estimates for scale up production vaccine introduction of an ebola vaccine.
Platform Technologies to Accelerate Novel Vaccine Development and ManufacturingMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3jmLYHu
State-of-the-art vaccine technologies are transforming vaccine development, and solutions for fast and reliable production are needed.
The vaccine industry has undergone a revolution in technology resulting in a variety of novel therapeutic platforms that accelerate development and significantly reduce the duration for process optimization and scale-up. However, challenges in maintaining efficacy and improving process robustness remain. In this presentation, we present a comparison of these novel technologies, discuss key considerations for manufacturing and share selected case studies for platforms such as virus-like-particles, viral vectors, plasmid DNA, and mRNA platform.
In this webinar, you will learn:
• Benefits of platform technologies in vaccine development
• Key considerations when deciding between platforms
• Vaccine pipeline analysis and selected case studies
Presented by:
David Loong, Ph.D, Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy
Josephine Cheng, Senior Consultant, Core Modalities Asia Pacific, Bioprocessing Strategy
In this webinar, you will learn:
Trends in vaccine manufacturing
Innovative solutions in facility design
Case studies and proposals for future vaccine factories
Considerations while setting up Quality Management Systems (QMSs)
How validation helps accelerate regulatory approval
Detailed description:
How we see vaccine manufacturing evolving due to the COVID-19 pandemic, how could it further transform, and what are some solutions we can incorporate to prepare ourselves for next-generation facilities?
The unprecedented COVID-19 pandemic has driven significant tech acceleration around the world, including methods of vaccine manufacturing. Together with the concept of Bioprocessing 4.0, digital biomanufacturing enables centralized orchestration of production process and data management, and a "Facility of the Future" characterized by intensified, continuous, predictive, and autonomous operations. In this presentation, we will explore trends in vaccine manufacturing, including fully single-use processes, closed processing, modular facilities, and platform manufacturing. We will also discuss some key considerations when setting up Quality Management Systems for novel facilities, and how to speed up regulatory approval through best practices in facility validation.
Webinar: Re-imagining vaccine manufacturing to address global health challengesMilliporeSigma
Participate in the interactive on demand webinar: http://bit.ly/ReimaginingVaccinesWebinar
In this webinar, you will learn:
- The evolution of vaccine production in response to pandemics and outbreaks
- Key considerations and perspectives on how vaccine processing and facilities could change to address future global health challenges
The document summarizes efforts to develop an HIV vaccine by inducing broadly neutralizing antibodies (bnAbs) through structure-based immunogen design. It describes how bnAbs isolated from infected individuals can inform design of immunogens that expose conserved vulnerabilities on HIV. Challenges include guiding antibody maturation along pathways to bnAbs and understanding how bnAbs develop naturally. Ongoing work includes defining HIV vulnerabilities with additional bnAbs and structures, understanding natural bnAb responses, epitope-directed and trimer-based immunogen design, and evaluating immunogens in collaboration between multiple research institutions. The goal is to develop an HIV vaccine to help curb the global AIDS pandemic.
Large-scale Production of Stem Cells Utilizing MicrocarriersZohaib HUSSAIN
Large-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing Microcarriers
viral vaccine production basics and manufacturing basics involved in development in research. Cell lines and characteristics of cell substrates and mode of operation useful for increased cell density. Basics of vaccine types and their features.
This document provides a high-level overview of the vaccine development process from research and testing in animals through clinical trials in humans and regulatory approval. It discusses key stages including preclinical research in animal models to test safety and efficacy, phases of human clinical trials, requirements for good manufacturing practices and regulatory compliance, and the role of quality assurance. It also provides examples of DVC's experience developing vaccines for biodefense threats like anthrax, smallpox, and plague.
COLDCHAIN“Bringing high-quality vaccines and refrigerated medicine to patient...Diego Alberto Tamayo
Create a system to track the temperature of vaccine using Smart IoT Edge
devices, Smart IoT cloud Eco Systems, Blockchain and Smart Analytics from
manufacturing to storage to transport to consumption – Reduce Wastage and
Improve distribution and lower Inventory!
NanoViricides is developing nanomedicine-based drugs to treat various viral diseases like influenza, HIV, hepatitis C, and Ebola. The company has 9 drug candidates in development that have shown safety and efficacy in animal studies. NanoViricides' first drug to enter human trials will be FluCide for influenza, which completely protected animals against lethal viral exposure without toxicity.
The document describes the industrial manufacturing process for vaccines. It involves upstream and downstream processes. Upstream involves selecting a seed strain, propagating microorganisms through cell culture or eggs, and isolating/purifying the microorganisms. Downstream involves inactivating organisms, formulating the vaccine, and performing quality control tests. An example of hepatitis B vaccine production using recombinant yeast is provided, involving strain selection, fermentation, antigen expression, purification, and formulation. Potential challenges discussed include vaccine hesitancy, ethical issues, inadequate preclinical data, and the need for new development techniques.
Imugene is developing B-cell peptide vaccines called mimotopes that induce a patient's own B-cells to produce antibodies targeting specific cancer antigens. Their lead candidate, HER-Vaxx, is a mimotope therapy for HER2-positive cancers that is designed to mimic the Herceptin antibody. A completed Phase 1 trial in breast cancer demonstrated HER-Vaxx was safe and induced anti-HER-2 antibodies and immune responses. Imugene is now conducting a Phase 1b/2 trial of HER-Vaxx in combination with chemotherapy in HER2-positive gastric cancer patients with results expected in 2018. The document provides an overview of Imugene's novel mimotope platform and its
This document provides an overview of Inovio Pharmaceuticals, a biotechnology company developing immunotherapies for cancer and infectious diseases using its proprietary SynCon® technology. Some key points:
- Inovio has generated best-in-class T cell responses and clinical efficacy in a phase II trial of its VGX-3100 immunotherapy for HPV-related cervical dysplasia.
- The company is advancing VGX-3100 into phase III and expanding into other HPV-related cancers as well as infectious diseases like HIV, hepatitis, Ebola, Zika, and MERS.
- Inovio has strategic partnerships with AstraZeneca and others valued up to $
Australian Business Forum helps Australian SMEs and businesses to understand the Chinese market and refine their China strategy.
http://abf.events/
ABOUT THE PRESENTATION
Presentation on Benitec Biopharma 'Gene Silencing for Life' including 'ddRNAi: A quiet revolution in therapeutics'
Presented by Bob Atwill, Senior Vice President of New Business & Collaborations
Presented at the Fortune Forum 2015 Australian Summit
Production and Purification of Virus Like Particle (VLP) based VaccineDr. Priyabrata Pattnaik
This document summarizes a presentation on the production and purification of virus-like particle (VLP) based vaccines. It discusses using hepatitis C VLPs as a model system produced using an insect cell/baculovirus expression platform. Key points covered include:
- Challenges in VLP vaccine production include low yields, stability issues, and difficulties removing baculovirus.
- Hepatitis C VLPs containing E1 and E2 glycoproteins were successfully produced using Sf9 insect cells in a Mobius 3L disposable bioreactor, with comparable results to a glass bioreactor.
- A depth filtration clarification process achieved around 70% DNA clearance while recovering approximately 70
Holistic Approaches to Virus Risk MitigationMilliporeSigma
Presented at INTERPHEX on March 21-23, 2017.
Regulatory guidelines have shaped industry best practices around adventitious virus contamination risk mitigation in terms of patient safety. A recent survey indicated that the cost to remediate a virus contamination can run into millions of dollars, not including commercial impact. Today, the industry is taking a closer look at minimizing the business risk associated with viral contaminations and is taking a more holistic view of risk mitigation. This approach includes virus prevention and detection in addition to removal. From cell culture seed train to final fill vial, the discussion will describe the potential risks associated with different areas of biotech processes and what can be done to minimize adventitious virus risk in those areas. The overarching strategy of risk mitigation will include evaluation of raw materials, modified expression systems, environmental controls, upstream and downstream processing, testing and regulatory considerations.
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...MilliporeSigma
Regulatory guidelines have defined industry best practices around adventitious virus contamination and risk mitigation in terms of patient safety.
Today, the industry is taking a closer look at minimizing the business risk associated with viral contamination and is taking a more directed view of risk mitigation. This approach includes virus prevention and detection, in addition to removal.
From cell culture seed train to final fill vial, this presentation will describe:
-Potential risks associated with different areas of biotech processes
-What can be done to minimize adventitious virus risk in those areas.
The overarching strategy of risk mitigation will include evaluation of raw materials, modified expression systems, environmental controls, upstream and downstream processing, as well as testing and regulatory considerations.
This document summarizes Inovio Pharmaceuticals' synthetic DNA vaccine technology and development pipeline. The technology is designed to generate robust immune responses, provide universal protection against infectious diseases, and treat cancers. Inovio has multiple vaccine candidates in clinical trials targeting cancers, influenza, HIV, and hepatitis B/C. The company is advancing discussions for partnerships and has received over $42 million in non-dilutive funding to support its programs.
This document summarizes Inovio Pharmaceuticals' synthetic DNA vaccine technology and development pipeline. The technology is designed to generate robust immune responses, provide universal protection against infectious diseases, and treat cancers. Inovio has multiple vaccine candidates in clinical trials targeting cancers, influenza, HIV, and hepatitis B/C. The company is advancing discussions for partnerships and has received over $35 million in non-dilutive funding to support its programs.
The document discusses Inovio's synthetic vaccine technology, which uses optimized DNA plasmids to generate targeted immune responses without using live or attenuated pathogens. Key points include:
- Inovio is developing synthetic vaccines for cancers, influenza, HIV, and hepatitis B/C using its proprietary SynCon platform and electroporation delivery technology.
- Clinical trials show Inovio's vaccines induce best-in-class immune responses compared to other vaccine technologies.
- The pipeline includes phase 2 vaccines for cervical dysplasia, leukemia, and hepatitis C, with efficacy data expected in 2013.
- The goal is to validate the platform and partner pipeline vaccines while advancing programs with non-dilutive funding.
Inovio is developing DNA-based immunotherapies and vaccines to treat cancers and infectious diseases. They have demonstrated efficacy of their VGX-3100 immunotherapy in a phase II trial for HPV-related cervical dysplasia. Inovio plans to start a phase III trial for VGX-3100 in 2017 and pursue other HPV-related indications. They are also developing immunotherapies for cancers in combination with checkpoint inhibitors, with a phase I/II trial starting in early 2017. In addition, Inovio is developing vaccines for infectious diseases like HIV, Ebola, Zika, and hepatitis B, with phase I data expected in 2017 that could support further development.
This document provides an overview of Inovio Pharmaceuticals and their DNA immunotherapy technology. Some key points:
- Inovio is developing DNA immunotherapies to generate targeted immune responses to prevent and treat cancers and infectious diseases. Their lead product VGX-3100 is in Phase II trials for HPV-associated precancers.
- Their approach uses optimized synthetic consensus DNA plasmids delivered intramuscularly with electroporation to produce targeted antigen-specific T-cell responses. This has shown best-in-class T cell responses in clinical trials.
- Upcoming milestones include Phase II efficacy data for VGX-3100 in mid-2014, additional cancer vaccine
The document summarizes recent advances at Inovio Pharmaceuticals, including being selected as a top translational researcher, generating immune responses in head and neck cancer patients, and protecting animals from Zika infection. It then discusses Inovio's plans to initiate a phase III trial for its HPV immunotherapy in 1H17 after an FDA request for additional information, and its partnership with MedImmune to develop immuno-oncology combination therapies. The document provides an overview of Inovio's immunotherapy technology platform and its potential applications in infectious diseases and cancer.
This document summarizes Inovio Pharmaceuticals' DNA immunotherapy platform and development pipeline. Key points include:
- Inovio is developing DNA immunotherapies to activate T cells in vivo to fight cancers and infectious diseases.
- Their platform focuses on designing DNA plasmids that can instruct the body's cells to produce antigens to activate targeted, durable immune responses.
- Their pipeline includes DNA vaccines and immunotherapies for HPV-related cancers and precancers, as well as programs in prostate, lung, breast, pancreatic, and head and neck cancers.
- A phase II trial of VGX-3100 for cervical dysplasia showed significant efficacy and led to a partnership
This document provides an overview of Inovio Pharmaceuticals' DNA immunotherapy platform and clinical programs. Key points include:
- Inovio is developing DNA-based immunotherapies to generate T-cell immune responses against cancers and infectious diseases.
- Their lead program, VGX-3100, showed positive Phase II efficacy results in treating HPV-related cervical dysplasia and aims to expand to other HPV-associated cancers.
- Other clinical programs include INO-3112 for cervical cancer, INO-1400 targeting hTERT for various cancers, and INO-1800 for hepatitis B.
- The document discusses attributes of an ideal T-cell generating immunotherapy and how Inovio
VGX-3100, Inovio's immunotherapy for HPV-associated cervical dysplasia, achieved statistically significant efficacy in a Phase II clinical trial. The treatment generated antigen-specific CD8+ killer T cells in vivo that regressed high-grade cervical dysplasia to low grade or normal in 49.5% of patients, compared to 30.6% for the control. This first-ever result validates Inovio's DNA-based immunotherapy platform and positions VGX-3100 for Phase III development as a potential non-surgical treatment for cervical dysplasia.
Inovio - Revolutionizing the Fight Against Cancers and Infectious DiseasesCompany Spotlight
This document provides an overview of Inovio Pharmaceuticals' DNA immunotherapy platform and clinical programs. It summarizes Inovio's lead product VGX-3100 for treating HPV-related cervical dysplasia and cancers. Phase II clinical trial results showed VGX-3100 significantly reduced cervical lesions and cleared HPV infections compared to placebo. The document discusses Inovio's expansion of HPV programs to other cancers and pre-cancers, as well as clinical trials in head and neck cancer and cervical cancer. It also summarizes Inovio's programs in hepatitis B and telomerase-associated cancers. The document positions Inovio's active DNA immunotherapy approach and T cell-generating platform technology as potentially addressing major
Large-scale Production of Stem Cells Utilizing MicrocarriersZohaib HUSSAIN
Large-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing Microcarriers
viral vaccine production basics and manufacturing basics involved in development in research. Cell lines and characteristics of cell substrates and mode of operation useful for increased cell density. Basics of vaccine types and their features.
This document provides a high-level overview of the vaccine development process from research and testing in animals through clinical trials in humans and regulatory approval. It discusses key stages including preclinical research in animal models to test safety and efficacy, phases of human clinical trials, requirements for good manufacturing practices and regulatory compliance, and the role of quality assurance. It also provides examples of DVC's experience developing vaccines for biodefense threats like anthrax, smallpox, and plague.
COLDCHAIN“Bringing high-quality vaccines and refrigerated medicine to patient...Diego Alberto Tamayo
Create a system to track the temperature of vaccine using Smart IoT Edge
devices, Smart IoT cloud Eco Systems, Blockchain and Smart Analytics from
manufacturing to storage to transport to consumption – Reduce Wastage and
Improve distribution and lower Inventory!
NanoViricides is developing nanomedicine-based drugs to treat various viral diseases like influenza, HIV, hepatitis C, and Ebola. The company has 9 drug candidates in development that have shown safety and efficacy in animal studies. NanoViricides' first drug to enter human trials will be FluCide for influenza, which completely protected animals against lethal viral exposure without toxicity.
The document describes the industrial manufacturing process for vaccines. It involves upstream and downstream processes. Upstream involves selecting a seed strain, propagating microorganisms through cell culture or eggs, and isolating/purifying the microorganisms. Downstream involves inactivating organisms, formulating the vaccine, and performing quality control tests. An example of hepatitis B vaccine production using recombinant yeast is provided, involving strain selection, fermentation, antigen expression, purification, and formulation. Potential challenges discussed include vaccine hesitancy, ethical issues, inadequate preclinical data, and the need for new development techniques.
Imugene is developing B-cell peptide vaccines called mimotopes that induce a patient's own B-cells to produce antibodies targeting specific cancer antigens. Their lead candidate, HER-Vaxx, is a mimotope therapy for HER2-positive cancers that is designed to mimic the Herceptin antibody. A completed Phase 1 trial in breast cancer demonstrated HER-Vaxx was safe and induced anti-HER-2 antibodies and immune responses. Imugene is now conducting a Phase 1b/2 trial of HER-Vaxx in combination with chemotherapy in HER2-positive gastric cancer patients with results expected in 2018. The document provides an overview of Imugene's novel mimotope platform and its
This document provides an overview of Inovio Pharmaceuticals, a biotechnology company developing immunotherapies for cancer and infectious diseases using its proprietary SynCon® technology. Some key points:
- Inovio has generated best-in-class T cell responses and clinical efficacy in a phase II trial of its VGX-3100 immunotherapy for HPV-related cervical dysplasia.
- The company is advancing VGX-3100 into phase III and expanding into other HPV-related cancers as well as infectious diseases like HIV, hepatitis, Ebola, Zika, and MERS.
- Inovio has strategic partnerships with AstraZeneca and others valued up to $
Australian Business Forum helps Australian SMEs and businesses to understand the Chinese market and refine their China strategy.
http://abf.events/
ABOUT THE PRESENTATION
Presentation on Benitec Biopharma 'Gene Silencing for Life' including 'ddRNAi: A quiet revolution in therapeutics'
Presented by Bob Atwill, Senior Vice President of New Business & Collaborations
Presented at the Fortune Forum 2015 Australian Summit
Production and Purification of Virus Like Particle (VLP) based VaccineDr. Priyabrata Pattnaik
This document summarizes a presentation on the production and purification of virus-like particle (VLP) based vaccines. It discusses using hepatitis C VLPs as a model system produced using an insect cell/baculovirus expression platform. Key points covered include:
- Challenges in VLP vaccine production include low yields, stability issues, and difficulties removing baculovirus.
- Hepatitis C VLPs containing E1 and E2 glycoproteins were successfully produced using Sf9 insect cells in a Mobius 3L disposable bioreactor, with comparable results to a glass bioreactor.
- A depth filtration clarification process achieved around 70% DNA clearance while recovering approximately 70
Holistic Approaches to Virus Risk MitigationMilliporeSigma
Presented at INTERPHEX on March 21-23, 2017.
Regulatory guidelines have shaped industry best practices around adventitious virus contamination risk mitigation in terms of patient safety. A recent survey indicated that the cost to remediate a virus contamination can run into millions of dollars, not including commercial impact. Today, the industry is taking a closer look at minimizing the business risk associated with viral contaminations and is taking a more holistic view of risk mitigation. This approach includes virus prevention and detection in addition to removal. From cell culture seed train to final fill vial, the discussion will describe the potential risks associated with different areas of biotech processes and what can be done to minimize adventitious virus risk in those areas. The overarching strategy of risk mitigation will include evaluation of raw materials, modified expression systems, environmental controls, upstream and downstream processing, testing and regulatory considerations.
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...MilliporeSigma
Regulatory guidelines have defined industry best practices around adventitious virus contamination and risk mitigation in terms of patient safety.
Today, the industry is taking a closer look at minimizing the business risk associated with viral contamination and is taking a more directed view of risk mitigation. This approach includes virus prevention and detection, in addition to removal.
From cell culture seed train to final fill vial, this presentation will describe:
-Potential risks associated with different areas of biotech processes
-What can be done to minimize adventitious virus risk in those areas.
The overarching strategy of risk mitigation will include evaluation of raw materials, modified expression systems, environmental controls, upstream and downstream processing, as well as testing and regulatory considerations.
This document summarizes Inovio Pharmaceuticals' synthetic DNA vaccine technology and development pipeline. The technology is designed to generate robust immune responses, provide universal protection against infectious diseases, and treat cancers. Inovio has multiple vaccine candidates in clinical trials targeting cancers, influenza, HIV, and hepatitis B/C. The company is advancing discussions for partnerships and has received over $42 million in non-dilutive funding to support its programs.
This document summarizes Inovio Pharmaceuticals' synthetic DNA vaccine technology and development pipeline. The technology is designed to generate robust immune responses, provide universal protection against infectious diseases, and treat cancers. Inovio has multiple vaccine candidates in clinical trials targeting cancers, influenza, HIV, and hepatitis B/C. The company is advancing discussions for partnerships and has received over $35 million in non-dilutive funding to support its programs.
The document discusses Inovio's synthetic vaccine technology, which uses optimized DNA plasmids to generate targeted immune responses without using live or attenuated pathogens. Key points include:
- Inovio is developing synthetic vaccines for cancers, influenza, HIV, and hepatitis B/C using its proprietary SynCon platform and electroporation delivery technology.
- Clinical trials show Inovio's vaccines induce best-in-class immune responses compared to other vaccine technologies.
- The pipeline includes phase 2 vaccines for cervical dysplasia, leukemia, and hepatitis C, with efficacy data expected in 2013.
- The goal is to validate the platform and partner pipeline vaccines while advancing programs with non-dilutive funding.
Inovio is developing DNA-based immunotherapies and vaccines to treat cancers and infectious diseases. They have demonstrated efficacy of their VGX-3100 immunotherapy in a phase II trial for HPV-related cervical dysplasia. Inovio plans to start a phase III trial for VGX-3100 in 2017 and pursue other HPV-related indications. They are also developing immunotherapies for cancers in combination with checkpoint inhibitors, with a phase I/II trial starting in early 2017. In addition, Inovio is developing vaccines for infectious diseases like HIV, Ebola, Zika, and hepatitis B, with phase I data expected in 2017 that could support further development.
This document provides an overview of Inovio Pharmaceuticals and their DNA immunotherapy technology. Some key points:
- Inovio is developing DNA immunotherapies to generate targeted immune responses to prevent and treat cancers and infectious diseases. Their lead product VGX-3100 is in Phase II trials for HPV-associated precancers.
- Their approach uses optimized synthetic consensus DNA plasmids delivered intramuscularly with electroporation to produce targeted antigen-specific T-cell responses. This has shown best-in-class T cell responses in clinical trials.
- Upcoming milestones include Phase II efficacy data for VGX-3100 in mid-2014, additional cancer vaccine
The document summarizes recent advances at Inovio Pharmaceuticals, including being selected as a top translational researcher, generating immune responses in head and neck cancer patients, and protecting animals from Zika infection. It then discusses Inovio's plans to initiate a phase III trial for its HPV immunotherapy in 1H17 after an FDA request for additional information, and its partnership with MedImmune to develop immuno-oncology combination therapies. The document provides an overview of Inovio's immunotherapy technology platform and its potential applications in infectious diseases and cancer.
This document summarizes Inovio Pharmaceuticals' DNA immunotherapy platform and development pipeline. Key points include:
- Inovio is developing DNA immunotherapies to activate T cells in vivo to fight cancers and infectious diseases.
- Their platform focuses on designing DNA plasmids that can instruct the body's cells to produce antigens to activate targeted, durable immune responses.
- Their pipeline includes DNA vaccines and immunotherapies for HPV-related cancers and precancers, as well as programs in prostate, lung, breast, pancreatic, and head and neck cancers.
- A phase II trial of VGX-3100 for cervical dysplasia showed significant efficacy and led to a partnership
This document provides an overview of Inovio Pharmaceuticals' DNA immunotherapy platform and clinical programs. Key points include:
- Inovio is developing DNA-based immunotherapies to generate T-cell immune responses against cancers and infectious diseases.
- Their lead program, VGX-3100, showed positive Phase II efficacy results in treating HPV-related cervical dysplasia and aims to expand to other HPV-associated cancers.
- Other clinical programs include INO-3112 for cervical cancer, INO-1400 targeting hTERT for various cancers, and INO-1800 for hepatitis B.
- The document discusses attributes of an ideal T-cell generating immunotherapy and how Inovio
VGX-3100, Inovio's immunotherapy for HPV-associated cervical dysplasia, achieved statistically significant efficacy in a Phase II clinical trial. The treatment generated antigen-specific CD8+ killer T cells in vivo that regressed high-grade cervical dysplasia to low grade or normal in 49.5% of patients, compared to 30.6% for the control. This first-ever result validates Inovio's DNA-based immunotherapy platform and positions VGX-3100 for Phase III development as a potential non-surgical treatment for cervical dysplasia.
Inovio - Revolutionizing the Fight Against Cancers and Infectious DiseasesCompany Spotlight
This document provides an overview of Inovio Pharmaceuticals' DNA immunotherapy platform and clinical programs. It summarizes Inovio's lead product VGX-3100 for treating HPV-related cervical dysplasia and cancers. Phase II clinical trial results showed VGX-3100 significantly reduced cervical lesions and cleared HPV infections compared to placebo. The document discusses Inovio's expansion of HPV programs to other cancers and pre-cancers, as well as clinical trials in head and neck cancer and cervical cancer. It also summarizes Inovio's programs in hepatitis B and telomerase-associated cancers. The document positions Inovio's active DNA immunotherapy approach and T cell-generating platform technology as potentially addressing major
Inovio is developing powerful DNA-based immunotherapy and vaccine platforms. They have shown clinical proof of concept for treating pre-cancerous conditions and generating antigen-specific CD8+ T cells in vivo. Their lead product VGX-3100 has achieved efficacy endpoints in a phase II cervical dysplasia trial and will enter phase III in 2016. Inovio is pursuing both monotherapy and combination approaches for cancer as well as partnerships with AstraZeneca and others. They have a broad pipeline of products in clinical trials for cancer and infectious diseases.
Inovio - Revolutionizing the Fight Against Cancers and Infectious DiseasesCompany Spotlight
- Dr. Joseph Kim presented on Inovio's DNA immunotherapy technologies and clinical pipeline.
- Their lead product, VGX-3100, met primary and secondary efficacy endpoints in a Phase II trial for treating HPV-related cervical dysplasia.
- Inovio is developing immunotherapies targeting HPV-related cancers and diseases, as well as cancers related to hTERT and prostate cancer, using their DNA plasmid vaccine approach coupled with electroporation delivery.
The document discusses developing vaccines for biodefense threats more rapidly using genome-derived epitope-driven vaccine (GD-EDV) design. Key components include immunoinformatics tools for epitope mapping, vaccine design algorithms, and rapid manufacturing once a pathogen genome is available. This approach aims to develop vaccines within 24 hours of obtaining a genome sequence to address urgent biothreats with unknown pathogens.
Dr. Joseph Kim, President & CEO of Inovio Pharmaceuticals, discussed Inovio's progress in developing DNA immunotherapies to treat cancers and infectious diseases. Key highlights included Phase II clinical trial results for VGX-3100 showing it met efficacy endpoints for treating HPV-related cervical dysplasia, additional cancer trials starting in 2014, and the potential for Inovio's therapies to provide non-surgical treatments and preventive vaccines. Inovio is a global leader in active immune therapies and aims to transform the fight against diseases through its SynCon DNA immunotherapy platform.
Inovio is developing DNA immunotherapies to prevent and treat cancers and infectious diseases. Their lead product, VGX-3100, is in Phase II trials for HPV-related cervical dysplasia and has the potential to treat several HPV-related cancers. Inovio uses optimized DNA plasmids delivered through electroporation to generate best-in-class T cell responses against targeted antigens. They have clinical data demonstrating the safety and strong immune responses induced by their approach. Inovio expects Phase II efficacy data for VGX-3100 in mid-2014, which could support advancing to Phase III trials and expanding the use of the product to other HPV-related conditions.
This document provides an overview of Inovio Pharmaceuticals, a company developing DNA-based immunotherapies and vaccines. It summarizes that Inovio is a global leader in active immune therapy, with the best T cell responses shown in clinical studies. It notes that key upcoming value drivers in 2014 include Phase II efficacy data for their lead drug VGX-3100 for cervical dysplasia, and the initiation of multiple new clinical trials for various cancer and infectious disease indications. The document emphasizes Inovio's ability to generate best-in-class T cell responses for immunotherapy using their proprietary DNA delivery technology and development of synthetic vaccines.
Revolutionizing the Fight Against Cancers and Infectious DiseasesCompany Spotlight
This document summarizes Inovio Pharmaceuticals' DNA immunotherapy platform and pipeline. It discusses Inovio's lead product VGX-3100, which demonstrated efficacy in treating HPV-related cervical dysplasia in a Phase II trial. Inovio is expanding VGX-3100 trials to other HPV-related cancers and preparing for Phase III. It also provides updates on Inovio's programs in HPV/cancer, hepatitis B, and cancer targeting hTERT. Inovio is advancing these programs through clinical trials while also developing new DNA immunotherapies and vaccines for additional infectious diseases and cancers.
Viral Challenge Studies: An Innovative Way to Speed Up Vaccine Development; A...SGS
In order to effectively fight influenza, the development of new, higher performing and universal vaccines is essential. However, clinical development is a lengthy and very expensive process, making it difficult for researchers to design vaccines for rapidly mutating viruses such as influenza. Assessing efficacy of a new influenza vaccine as early as possible in the development, to make a first selection and an early ‘go – no go’ decision, is key. Viral Challenge studies are an important tool to aid in the swift development of effective influenza vaccines particularly for potential pandemics like the avian influenza (bird flu).
Inovio is developing DNA-based immunotherapies and vaccines to treat cancers and infectious diseases. Their lead product, VGX-3100, met its primary and secondary efficacy endpoints in a Phase II clinical trial for treating cervical dysplasia caused by HPV infection. The trial showed VGX-3100 significantly reduced cervical lesions and cleared HPV infection compared to the placebo. Inovio is also developing DNA vaccines and immunotherapies for HPV-related cancers, hepatitis B, hepatitis C, HIV, Ebola, and others. Their proprietary SynCon® technology allows for optimized antigen design and electroporation enhances antigen expression and immune responses. Inovio aims to be the best-in-class
VGX-3100, Inovio's DNA immunotherapy, showed promising results in treating cervical dysplasia in a Phase II clinical trial. The trial met its primary endpoint, with 49.5% of VGX-3100 patients experiencing regression of high-grade cervical lesions to CIN1 or normal tissue, compared to 30.6% of placebo patients. VGX-3100 also met secondary endpoints including clearance of HPV 16 and 18. Additional analysis found the treatment generated HPV-specific T cell responses and CD8 T cells were present in cervical tissue of treated patients. Based on these results, Inovio is expanding trials of VGX-3100 to treat other HPV-associated cancers and moving
Similar to Inovio Pharmaceuticals 2012 Investor Presentation (20)
Presentation Clayton Valley, NevadaFrom Drilling to PEA in under 2 YearsCompany Spotlight
The document summarizes Cypress Development Corp's Clayton Valley lithium project in Nevada. Key points include:
- A Preliminary Economic Assessment shows promising economics including a 32.7% IRR and $1.45 billion NPV.
- Measured and indicated resources total 8.9 million tonnes LCE with additional inferred resources.
- The project has the potential for low-cost production due to favorable geology and metallurgy.
- Upcoming catalysts in 2019 include a metallurgical study and prefeasibility study to further de-risk the project.
Aben Resources has made a new high-grade gold discovery at its flagship Forrest Kerr project in BC's Golden Triangle region. The region is known for major gold deposits and saw $100 million in exploration spending in 2017. Recent improvements have made the Forrest Kerr project more accessible via new roads. Aben's technical team has reinterpreted historical data and identified additional exploration targets. The project covers over 23,000 hectares of prospective geology along the Forrest Kerr fault zone that is similar to other major deposits in the Golden Triangle.
Aben Resources has discovered high-grade gold zones at its Forrest Kerr project in British Columbia's Golden Triangle. The first hole of the 2018 drill program intersected four separate high-grade gold zones within 190 metres, including 331.0 g/t Au over 1.0 metre. Aben plans to expand drilling at the Boundary North Zone and test other gold anomalies identified through soil sampling. The company also holds the Justin project in Yukon and Chico project in Saskatchewan near recent discoveries.
Cypress Development Corp. owns lithium claims in Clayton Valley, Nevada near Albemarle's Silver Peak lithium mine. A preliminary economic assessment found the project could have a 32.7% IRR and $1.45 billion NPV. The project would extract lithium from claystone using leaching and have average annual production of 24,042 tonnes of lithium carbonate over 40 years. Capital costs are estimated at $482 million to build a 15,000 tonne per day operation.
The document discusses Aben Resources Ltd., a gold exploration company with projects in British Columbia's Golden Triangle region and other areas of Western Canada. It provides an overview of Aben's management team and directors, flagship Forrest Kerr project, recent drilling results showing new high-grade gold discoveries, and its strategy to advance exploration through 2018. The document also briefly outlines Aben's other projects including the Chico gold project in Saskatchewan and Justin gold project in Yukon.
Cypress Development Corp. owns the Clayton Valley lithium project in Nevada. Drilling in 2017 intersected lithium-bearing claystone averaging 921 ppm Li over 77 meters thick. A maiden resource estimate calculated 3.287 million tonnes of lithium carbonate equivalent in the indicated category and 2.916 million tonnes LCE in inferred. Metallurgical tests show the claystone is acid leachable and able to recover over 80% of the lithium. Cypress plans additional drilling, engineering studies, and permitting to advance the project towards production.
- Aben Resources has three highly prospective gold projects in Western Canada including its flagship Forrest Kerr Project in BC's Golden Triangle region, which had recent drilling success expanding the Boundary North Zone.
- Management has over 100 years of combined experience in Western Canada and a proven track record of success.
- The projects have significant historic work identifying high-grade gold and robust discovery potential remains.
Cypress Development Corp. owns the Clayton Valley lithium project in Nevada. Drilling in 2017 intersected lithium-bearing claystone averaging 921 ppm Li over 77 meters. A maiden resource estimate classified over 1.3 million tonnes of lithium carbonate equivalent as indicated and inferred. Metallurgical testing shows the claystone is leachable with over 80% lithium recovery. Cypress aims to advance the project with engineering studies and further drilling to define resources with the goal of becoming a domestic lithium producer for the growing battery market.
The document provides forward-looking statements and discusses risks associated with such statements. It notes that some statements may be deemed forward-looking and lists factors that could cause actual results to differ from forward-looking statements. The document also identifies the qualified person for the technical information as Cornell McDowell and provides Aben's trading symbols and recent share information.
The document provides an overview of Aben Resources Ltd., a mineral exploration company with gold projects in Western Canada. It summarizes Aben's three key projects - Forrest Kerr in BC's Golden Triangle region with recent drill results discovering the Boundary Zone, Chico in Saskatchewan near producing mines, and Justin in Yukon's White Gold district. It outlines the management team's expertise and provides company details like shares outstanding and trading symbols.
- Cypress Development Corp owns the Clayton Valley lithium project in Nevada located near Albemarle's Silver Peak lithium brine operation.
- Drilling in 2017 encountered lithium mineralization averaging 921 ppm Li over 77 meters in 14 holes drilled.
- Metallurgical tests show the claystone is acid leachable with over 80% lithium extraction possible.
- Cypress aims to define a resource estimate in 2018 and advance the project with feasibility studies to develop a lithium operation.
The document discusses forward-looking statements and provides disclaimers about them. It introduces the qualified person for the technical information presented. It also lists Aben's trading symbols and recent share information including price and market capitalization.
1) Cypress Development Corp owns the Clayton Valley lithium project located next to Albemarle's Silver Peak mine in Nevada. Drilling in 2017 intersected lithium-bearing claystone averaging over 900 ppm Li to a depth of over 100 meters.
2) A maiden resource estimate classified over 1.5 million tonnes of lithium carbonate equivalent as indicated and inferred. Metallurgical testing shows the claystone is acid leachable to extract over 80% of the lithium.
3) The project is located in a strategic location to supply the growing lithium-ion battery market in the US, with lithium demand accelerating due to the increased production of electric vehicles globally.
TerraX Minerals is a Canadian mineral exploration company focused on exploring and developing its 100% owned 772 square km Yellowknife City Gold project located adjacent to the city of Yellowknife, Northwest Territories. The project covers high-grade Archean gold districts and has had multiple high-grade gold discoveries. TerraX has a strong management team with experience discovering and developing gold deposits and low exploration costs due to the project's excellent infrastructure and year-round access near Yellowknife.
This document discusses forward-looking statements and provides information about Aben Resources Ltd., including its stock symbols, shares outstanding, recent share price, market capitalization, and three gold exploration projects in Western Canada. It summarizes the management team's experience and the company's investment highlights. Specifically, it owns the Forrest Kerr gold project in British Columbia's Golden Triangle region, which saw successful drilling results in 2017 that led to a new discovery called the North Boundary zone.
Cypress Development Corp owns lithium claystone deposits in Clayton Valley, Nevada near Albemarle's Silver Peak lithium mine. Drilling in 2017 encountered lithium mineralization averaging 921 ppm Li over 77 meters in 14 holes. Metallurgical tests show the claystone is acid leachable with up to 80% lithium extraction. Cypress plans additional drilling, process engineering, and a preliminary economic assessment in 2018 to advance the project. The company sees potential for the project given growing lithium demand from electric vehicles and batteries.
TerraX Minerals is a Canadian mineral exploration company focused on exploring its 100% owned 772 square km Yellowknife City Gold project located near Yellowknife, Northwest Territories. The project covers high-grade Archean gold districts with known deposits and past producers. TerraX has made multiple high-grade gold discoveries on the property and identified several high-priority targets for further exploration and drilling. The company has a strong management team with experience discovering and developing deposits in the region.
Cypress Development Corp owns lithium claystone deposits in Clayton Valley, Nevada that have the potential to be a significant lithium resource. Drilling in 2017 encountered mineralization averaging 921 ppm lithium over 77 meters thick in 14 drill holes. Metallurgical testing shows the claystone is acid leachable with up to 80% lithium extraction. Cypress plans additional drilling, metallurgical testing, and a preliminary economic assessment in 2018 to further define the resource potential.
Cypress Development Corp owns lithium claystone deposits in Clayton Valley, Nevada near Albemarle's Silver Peak lithium mine. Drilling in 2017 encountered mineralization averaging 921 ppm lithium over 77 meters thick in 14 drill holes. Metallurgical tests show the claystone is acid leachable with up to 80% lithium extraction. Cypress plans additional drilling, metallurgical testing, and a preliminary economic assessment in 2018 to evaluate the project's potential.
Cypress Development Corp is exploring for lithium resources in Clayton Valley, Nevada. Recent drilling has encountered lithium-bearing claystone up to 112 meters below surface, with grades averaging over 800 ppm lithium. Metallurgical testing indicates 80% of the lithium can be extracted using a weak sulfuric acid solution. Cypress plans additional drilling in 2018 and expects to publish a initial lithium resource estimate in Q1 2018 to advance the project towards a preliminary economic assessment. The project is located near existing lithium production and infrastructure to be a potential new supply of lithium for the growing battery market.
2. Forward Looking Statement
Our commentary and responses to your questions may contain forward-looking
statements, including comments concerning clinical trials and product
development programs, evaluation of potential opportunities, the level of
corporate expenditures, the assessment of Inovio’s technology by potential
corporate partners, capital market conditions, timing of events, cash
consumption and other subjects. Information concerning factors that could
cause actual results to differ materially from those set forth in our Annual
Report on Form 10-K for the year ended December 31, 2011, our Form 10-Q
for the quarter ended June 30, 2012, and other regulatory filings from time to
time.
Page 2
3. Inovio: Revolutionizing Vaccines
• Inovio’s synthetic vaccine technology designed to:
• Treat some of today’s most challenging diseases
• Universally protect against changing infectious disease strains
• Break the body’s tolerance of cancerous cells
• Targeting unmet needs with multi-billion dollar potential:
cancers, universal flu, HIV, hepatitis B/C virus
• Multiple ongoing clinical trials: phase II and phase I
• Industry-leading potency & safety
• Best-in-class immune responses for cervical dysplasia & HIV
• Dominant global IP position (424 patents issued/pending)
• Validation:
• $35M+ in non-dilutive grant funding over last few years
• Advancing discussions for vaccine product development
partnerships and further grant funding
Page 3
4. Conventional Vaccines
Increased life expectancy
• Saved millions from sickness/death
• Added decades to life expectancy
• Deliver a virus or part of a virus to
expose a unique antigen (foreign
protein)
• Generate antibodies that prevent
targeted diseases from infecting cells
• Low hanging fruit picked – old Five decade-old technology is great . . .
technology has reached its limitations but does not solve tomorrow’s challenges
• Safety concerns: can cause the
disease or other bad side effects
• Rely on technology that is often more
than 50 years old; some vaccines are
still grown in chicken eggs
Page 4
5. Synthetic DNA Vaccine Platform
Revolutionizing vaccines through:
• Strong safety profile
• SynCon® “designer vaccines” give the body the DNA instructions to produce only the
targeted antigen - nothing more
• Generate powerful T-cells to kill infected cells or tumors (therapeutic vaccines)
• Manufacturing advantages: rapid, scalable, thermal-stable
Page 5
6. SynCon® Universal Vaccine Design
Immune responses more cross-reactive (universal)
than those induced by single-strain vaccines Page 6
8. Best-in-Class Immune Responses in Humans
Immune Responses
T Cell Responses Antibody Responses
Inovio Clinical Clinical Results Competition Inovio Clinical Clinical Competition
Study Study Results
HPV-001 Best in class T Adenovirus vectors FLU-001/002 Broad Stockpiled
Cervical cell responses MVA vectors H5N1 protective inactivated
Cancer/ (magnitude and DNA vaccines Pandemic Flu antibody vaccines
Dysplasia durability) Peptides/proteins titers against
6 different
H5N1 strains
HVTN-080 Best in class T Adenovirus vectors FLU-101 Broad Trivalent
Preventive HIV cell responses MVA vectors Universal Flu – protective inactivated
Vaccine (magnitude and DNA vaccines H1N1 antibody virus vaccines
durability) Peptides/proteins titers against (TIV)
Combinations 9 different Live-attenuated
H1N1 strains vaccines
Page 8
9. Inovio’s Strategy
• Advance/validate SynCon® + electroporation platform
• Best in-class immunogenicity established in human studies
• Develop proprietary products through proof-of-concept
human data (phase I or phase II)
• Maximize resources/opportunities; spread cost/risk
• Non-dilutive third party funding
• Direct: R&D grants
– $35M received since 2008
• Indirect: clinical trials sponsored by outside agencies
– Seven ongoing studies
• Partner/out-license product for preclinical/clinical
development and marketing
Page 9
10. Inovio Product Pipeline: Cancers
Pre-
Indication Product (Antigen) Phase I Phase II Partner/Funding Milestone
clinical
Cervical Dysplasia VGX-3100 (E6/E7 2H 2013
Therapeutic Type 16/18 HPV) Phase II study data
(Wilms’ tumor University of 4Q 2012
Leukemia
Cancers
gene 1) Southampton Interim Phase II data
INO-5150 1H 2013
Prostate
(PSA + PSMA) Initiate Phase I
Breast/Lung/ V934
Merck
Prostate (hTERT)
Internally Funded
Page 10
Partner Funded/Supported
11. Inovio Product Pipeline: Infectious Diseases
Pre-
Indication Product (Antigen) Phase I Phase II Partner/Funding Milestone
clinical
4Q 2012
(NS3/4A) + SOC ChronTech Phase II interim data
Hepatitis C Virus
Therapy PA CARE Grant/ 2H 2013
INO-8000
(NS3/4A, NS4B, NS5A) VGX Inter Initiate Phase I
Phase I final data
HIV Vaccine
PENNVAX-B submitted for
Trials Network
publication
HIV Preventive 1H 2013 Additional
Infectious Diseases
PENNVAX-G USMHRP/NIAID
Phase I data
1Q 2013
PENNVAX-GP NIH/NIAID
Initiate Phase I
University of 4Q 2012
HIV Therapeutic PENNVAX-B Final Phase I data
Pennsylvania
Pandemic Influenza Manuscript in
VGX-3400X preparation
-Avian (H5N1)
Universal Influenza – NIH Transformative 1Q 2013
INO-3510
Healthy Adults Research Award Add’l Phase I data
U. of Manitoba/
Universal Influenza – 1Q 2013
FVH1 Canadian Institute of
(H1N1) in Elderlies Interim Phase I data
Health Research
Internally Funded
Page 11
Partner Funded/Supported
12. VGX-3100: Cervical Dysplasia/Cancer Therapy
• Cervical cancer: ~500,000 cases, 250,000 deaths yearly
• Cervical dysplasias (CIN) preceding cancer (U.S. annually)
• CIN 1: 1.4 M ; CIN 2/3: 300,000
• VGX-3100 phase I
• 18 patients, 3 dose levels
• Vaccine safe and well-tolerated
• Most robust T-cells generated by T cell
a DNA vaccine in humans responses
by other
• Stronger responses than other Low Mid High All
vaccines
Dose Level
vaccines, including viral vectors
• Strong T-cell response in 14 of 18
(78%) vaccinated subjects at month 4
• Durable responses: 12 of 13 responders (92%) displayed
persistent, strong T-cell responses at month 9
Page 12
13. VGX-3100: Phase II Study
• Randomized, blinded, placebo controlled
• > 25 sites in multiple countries
• 148 patients with CIN 2/3
• Three vaccinations over 3 months, 6 months monitoring
• Primary endpoint: CIN 2/3 lesion clearance at month 9
• Initiated in 2011; enrollment ongoing
• Efficacy data expected 2H 2013
Page 13
14. Leukemia Vaccine: Phase II
• Chronic myeloid leukemia (CML) 300,000+ new cases,
• Acute myeloid leukemia (AML) 222,000 deaths yearly
• Vaccine coded for Wilms’ tumor gene 1 (WT1)
• Overexpressed in majority of acute leukemias
• Open label phase II clinical trial
• Active: 37 CML patients, 37 AML patients
• Control group: 100-110 AML/CML patients, non-vaccinated
• Primary endpoints
• CML: molecular response to disease marker (BCR-ABL)
• AML: time to disease progression
• Initiated in 2011; enrollment ongoing; interim data expected 4Q 2012
Page 14
15. ChronVac-C® Therapeutic Vaccine
• Hepatitis C virus (HCV)
• 3.5 million chronically infected in US; >170 million worldwide
• Causes liver disease/cancer
• Positive phase I study (HCV genotype 1): ChronVac-C + standard of care (SOC:
interferon & ribavirin)
• Safe & well-tolerated
• Positive T-cell immune responses
• Sustained viral response (SVR): 5 of 6 patients (83%)
• Open label, randomized phase II study (32 patients)
• Vaccinated (20): 2 vaccinations; Control (12): SOC only
• Primary endpoints
• Rapid viral response (4 weeks)
• Partial early viral response (pEVR) (12 weeks)
• Initiated in 2011; enrollment ongoing
• Interim data expected 4Q 2012
Page 15
16. PENNVAX-B: Phase I Studies
• Preventive study, randomized, placebo-controlled: run by HVTN
• Three vaccinations over 3 months; 48 vaccinated subjects, 3 arms:
• 1 mg PENNVAX-B (n=10)
• 1 mg PENNVAX-B + DNA IL-12 delivered via EP (n=30)
• Placebo (n=8)
• T-cell immune responses superior to all other previously-tested HIV vaccines
• Submitted for publication
T-cell Responses
by intracellular cytokine staining (ICS) assay
Positive Reponses Placebo Group Vaccine + DNA IL-12 + EP
Total CD4 + CD8 0% (0/8) 88.9% (24/27)
__________________________________________________________________
__________________________________________________________________
• Therapeutic study, open label, 12 vaccinated subjects, run by UPenn
• Significant antigen-specific CD8+ T-cell responses:
• against at least 1 of 3 antigens (gag, pol, or env) in 75% of subjects
Page 16
17. SynCon® Universal Influenza Vaccines
• H5N1 phase I data:
• Strong T-cell/antibody responses
• => 1:20 HAI titers – 71% positive
responders to at least 1 H5N1 virus
• Protection against all six
unmatched H5N1 strains tested
• H1N1 phase I data:
• Significant # of responders
exceeding 1:40 HAI titers against
different strains
• Protection against all nine
unmatched H1N1 strains tested
Potential to shift flu vaccination
from “one bug, one drug” approach to
pre-emptive, universal prevention across
strains, subtypes and years Page 17
18. Management
J. Joseph Kim, Ph.D., President & Peter Kies, CFO
CEO
• Decades of biotechnology/pharma • Ex-Ernst & Young
management • Experience with growth companies
• Ex-Merck: hepatitis A and B vaccines
manufacturing; HIV vaccine (Ad5)
R&D
Niranjan Y. Sardesai, Ph.D., COO Mark L. Bagarazzi, M.D., CMO
• Extensive biotech management • Clinical research experience incl.
and product development Merck
experience • Led clinical/regulatory for shingles
• Led development of diagnostics and rotavirus vaccines; DNA vaccine
for mesothelioma, bladder expert
cancer, and ovarian cancer for
Fujirebio Diagnostics
Managed development and approval of several vaccines Page 18
19. Board of Directors
Avtar Dhillon, M.D., Chairman, BOD Morton Collins, Ph.D.
• Former President & CEO, Inovio • General Partner, Battelle Ventures
Biomedical and Innovations Valley Partners
Simon X. Benito J. Joseph Kim, Ph.D.
• Former Senior Vice President, Merck • President & CEO, Inovio
Vaccine Division
Angel Cabrera, Ph.D. Adel Mahmoud, Ph.D.
• President, George Mason University • Professor, Princeton University
• Former President, Thunderbird School • Former President, Merck Vaccines
of Global Management • Responsible for Gardasil®, Zostavax®,
Proquad® and Rotateq®
Page 19
20. Scientific Advisory Board
David B. Weiner, Ph.D., Chairman, SAB
• “Father of DNA vaccines”
• Dept. of Pathology & Laboratory
Medicine, U of PA
Thomas S. Edgington, M.D. Philip Greenberg, M.D.
• Founded multiple biotech companies; • Expert in T-cell immunology
extensively published • Head, Immunology Program, Fred
• Emeritus Professor, Scripps Research Hutchinson Cancer Research Center
Institute
Anthony W. Ford-Hutchinson, Ph.D. Stanley A. Plotkin, M.D.
• Former SVP, Vaccines R&D, Merck • Developed rubella and rabies vaccines
• Oversaw development: Singulair®, • Oversaw Sanofi flu vaccine
Januvia®, Gardasil®, Zostavax®, • Emeritus Professor, Wistar Institute &
Proquad® and Rotateq® U of Penn
Page 20
21. Financial Information
Cash & short term investments1 $19.5 M
Debt1 0M
Burn rate ~$4.5 M/Q
Cash runway 3Q 2013
Listing NYSE MKT: INO
Issued & outstanding shares1 134.9 M
Recent price2 $0.63
Market cap2 $85 M
1 June 30, 2012 2 September 18, 2012
Page 21
22. Investment Summary
• Paradigm shifting synthetic vaccine platform displaying best-in-
class immunogenicity and other characteristics significantly
improving upon conventional and new competitive vaccine
technologies
• Strong management team with vast vaccine discovery &
development expertise
• Extensive third-party grant funding
• Important validating clinical milestones over next quarters
• Advancing discussions with large pharmaceutical
companies with the goal of securing new partnerships to
advance development and commercialization of SynCon®
vaccines
Page 22